

12-4137: Phospho-Lck (Tyr505) (Clone: A3) rabbit mAb

Clonality :	Monoclonal
Clone Name :	LckY505-A3
Application :	FACS,WB
Reactivity :	Human
Conjugate :	Unconjugated
Format :	Purified
Alternative Name :	Tyrosine-protein kinase Lck, Leukocyte C-terminal Src kinase, LSK, Protein YT16, T cell-specific protein-tyrosine kinase
Isotype :	Rabbit lgG1k
Immunogen Information	A synthetic phospho-peptide corresponding to residues surrounding Tyr505 of human phospho Lck

Description

Lck is a member of the Src family of non-receptor tyrosine kinases and plays a major role in T cell activation. Lck activates many downstream signaling pathways including Akt/mTOR, SAPK/JNK, PLCg1, and RAS/MAPK. Phosphorylation of Lck at Tyr394 in the catalytic domain at the ATP-binding site stabilizes the open and active form, while phosphorylation at Tyr505 in the C-terminal domain promotes the closed, inactive conformation. Multiple small-molecule drugs used to treat leukemia have been shown to target inhibition of Lck, including imatinib and dasatinib. Lck is thus a promising target for suppressing T-cell responses for the treatment of inflammatory diseases or after organ transplantation.

Product Info

Amount :	20 μl / 200 μl
Content :	1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA
Storage condition :	Store at -20°C. Avoid repeated freeze and thaw cycles.

Application Note

1Ã[]µg/mL - 0.001Ã[]µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.(0.5mg/ml, more than 200 western blots)





Fig-1: Flow cytometric analysis of Daudi cells secondary antibody only negative control (blue) or untreated (red) or treated with IFNa + IL-4 + pervanadate (green) using Phospho-Lck (Tyr505) antibody LckY505-A3 at 1 μ g/mL.

w abeomics

9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982 Email: info@abeomics.com



40-

30

+

40-

30

20-

+ – CalA

Fig 2 : Western blot analysis of Jurkat cell extract untreated or treated with 200nM calyculin A for 30min using Phospho-Lck (Tyr505) antibody LckY505-A3 at 0.1 μ g/mL.

Fig-3: Peptide blocking flow cytometric analysis of Daudi cells secondary antibody only negative control (light blue) or untreated (red) or treated with IFNa + IL-4 + pervanadate (green) or untreated and blocked with phospho-peptide (black) or treated and blocked with phospho peptide (gold) or untreated and blocked with nonphospho peptide (dark blue) or treated and blocked with non-phospho peptide (purple) using Phospho-Lck (Tyr505) antibody LckY505-A3 at 1 µg/mL.

Fig-4: Western blot analysis of Jurkat cell extract, untreated or treated with calyculin A using 0.1 μ g/mL Phospho-Lck (Tyr505) antibody LckY505-A3 or Company C antibody at 1 μ g/mL (manufacturer's recommended concentration) developed using the same exposure.